Medicine and Dentistry
Emricasan
100%
Liver Cirrhosis
40%
Placebo
40%
Nonalcoholic Fatty Liver
30%
Decompensated Liver Cirrhosis
30%
Clinical Trial
30%
End Stage Liver Disease
20%
Liver Function
20%
Therapeutic Procedure
20%
Patient
20%
Inpatient
20%
Serositis
10%
Hazard Ratio
10%
Serum
10%
Group Therapy
10%
Bleeding
10%
Programmed Cell Death
10%
Child-Pugh Score
10%
Hepatocellular Carcinoma
10%
Hepatic Encephalopathy
10%
Portal Hypertension
10%
Sodium
10%
Albumin
10%
All Cause Mortality
10%
Placebo-Controlled Study
10%
Fatty Liver
10%
Diuretic Agent
10%
Model for End-Stage Liver Disease
10%
Liver Cell Damage
10%
Ascites
10%
Bilirubin
10%
Portal Venous Pressure
10%
Caspase Inhibitor
10%
Hepatorenal Syndrome
10%
Spontaneous Bacterial Peritonitis
10%
Carbon Tetrachloride-Induced Liver Cirrhosis
10%
Amaurosis
10%
Pharmacology, Toxicology and Pharmaceutical Science
Emricasan
100%
Liver Cirrhosis
40%
Decompensated Liver Cirrhosis
30%
Nonalcoholic Fatty Liver
30%
End Stage Liver Disease
20%
Albumin
10%
Sodium
10%
Placebo-Controlled Study
10%
Bleeding
10%
Diuretic Agent
10%
Ascites
10%
Mouse
10%
Liver Cell Carcinoma
10%
Hepatic Encephalopathy
10%
All Cause Mortality
10%
Bilirubin
10%
Portal Hypertension
10%
Caspase Inhibitor
10%
Fatty Liver
10%
Bacterial Peritonitis
10%
Liver Cell Damage
10%
Lipotoxicity
10%
Hepatorenal Syndrome
10%
Carbon Tetrachloride-Induced Liver Cirrhosis
10%
Death
10%
Blindness
10%
Biochemistry, Genetics and Molecular Biology
Liver Function
20%
Apoptosis
10%
Caspase
10%
Portal Vein Blood Pressure
10%
Mouse
10%
Bilirubin Blood Level
10%
Lipotoxicity
10%
All Cause Mortality
10%
Albumin Level
10%